[go: up one dir, main page]

MX2019013192A - Método de tratamiento y diseño de ensayo clínico para la atrofia geográfica debida a la degeneración macular relacionada con la edad. - Google Patents

Método de tratamiento y diseño de ensayo clínico para la atrofia geográfica debida a la degeneración macular relacionada con la edad.

Info

Publication number
MX2019013192A
MX2019013192A MX2019013192A MX2019013192A MX2019013192A MX 2019013192 A MX2019013192 A MX 2019013192A MX 2019013192 A MX2019013192 A MX 2019013192A MX 2019013192 A MX2019013192 A MX 2019013192A MX 2019013192 A MX2019013192 A MX 2019013192A
Authority
MX
Mexico
Prior art keywords
brimonidine
age
geographic atrophy
macular degeneration
clinical trial
Prior art date
Application number
MX2019013192A
Other languages
English (en)
Inventor
Kerr Kevin
Lopez Francisco
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of MX2019013192A publication Critical patent/MX2019013192A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Pathology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)

Abstract

Métodos para tratar o ralentizar el crecimiento de una lesión asociada con la atrofia geográfica y métodos para evaluar un fármaco o agente para su uso en tratar, reducir el avance de o ralentizar el crecimiento de una lesión asociada con la atrofia geográfica.
MX2019013192A 2017-05-05 2018-05-04 Método de tratamiento y diseño de ensayo clínico para la atrofia geográfica debida a la degeneración macular relacionada con la edad. MX2019013192A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762502375P 2017-05-05 2017-05-05
PCT/US2018/031048 WO2018204759A1 (en) 2017-05-05 2018-05-04 Brimonidine for use and clinical trial design for geographic atrophy due to age-related macular degeneration

Publications (1)

Publication Number Publication Date
MX2019013192A true MX2019013192A (es) 2020-01-13

Family

ID=62555156

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019013192A MX2019013192A (es) 2017-05-05 2018-05-04 Método de tratamiento y diseño de ensayo clínico para la atrofia geográfica debida a la degeneración macular relacionada con la edad.

Country Status (14)

Country Link
US (2) US20180318302A1 (es)
EP (1) EP3618832A1 (es)
JP (1) JP2020518626A (es)
KR (1) KR20190142399A (es)
CN (1) CN110769829A (es)
AU (1) AU2018261171A1 (es)
BR (1) BR112019023223A2 (es)
CA (1) CA3062455A1 (es)
CL (1) CL2019003172A1 (es)
MX (1) MX2019013192A (es)
PH (1) PH12019502483A1 (es)
RU (1) RU2019136781A (es)
WO (1) WO2018204759A1 (es)
ZA (1) ZA201907329B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115485717A (zh) * 2020-03-23 2022-12-16 基因泰克公司 使用分割和特征评估预测地图状萎缩进展
CN113035298B (zh) * 2021-04-02 2023-06-20 南京信息工程大学 递归生成大阶数行限制覆盖阵列的药物临床试验设计方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8969415B2 (en) * 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
HK1218850A1 (zh) * 2013-02-15 2017-03-17 Allergan, Inc. 持续药物递送植入物

Also Published As

Publication number Publication date
AU2018261171A1 (en) 2019-12-05
BR112019023223A2 (pt) 2020-05-26
CN110769829A (zh) 2020-02-07
WO2018204759A1 (en) 2018-11-08
EP3618832A1 (en) 2020-03-11
RU2019136781A (ru) 2021-06-07
US20210213017A1 (en) 2021-07-15
CL2019003172A1 (es) 2020-04-13
CA3062455A1 (en) 2018-11-08
KR20190142399A (ko) 2019-12-26
ZA201907329B (en) 2021-05-26
US20180318302A1 (en) 2018-11-08
PH12019502483A1 (en) 2020-07-20
JP2020518626A (ja) 2020-06-25

Similar Documents

Publication Publication Date Title
MX2024007658A (es) Composiciones y metodos de uso de nintedanib para mejorar el exito de la cirugia del glaucoma.
SG10201908697XA (en) A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
MX2019001517A (es) Complejos de nanopartículas de albúmina modificada con anticuerpos para el tratamiento del cáncer.
HK1217490A1 (zh) 黃斑變性治療中的新穎捕獲劑
MX2021001169A (es) Formas sólidas de ácido {[5-(3-clorofenil)-3-hidroxipiridin-2-carb onil]amino}acético, composiciones, y usos de las mismas.
HK1220980A1 (zh) 用於治疗庞贝氏症的方法和组合物
MX2015015518A (es) Metodos y composiciones para el tratamiento del cancer.
CL2015002835A1 (es) Nuevos derivados de piridina
EA033446B1 (ru) Гетероциклическое соединение для лечения дегенерации желтого пятна и/или болезни штаргардта
WO2015066302A3 (en) Compositions, methods of use, and methods of treatment
MX2016009251A (es) Derivados de 7-oxo-1, 6-diazabiciclo [3.2.1] octano y su uso como agentes antibacterianos.
WO2015123449A3 (en) Compositions and methods of using microrna inhibitors
AU2015267099A8 (en) Use of eribulin in the treatment of cancer
PH12018502161A1 (en) Methods of treatment for cholestatic and fibrotic diseases
PH12016502243A1 (en) Pharmaceutical compositions for treating infectious diseases
PH12016501349A1 (en) Hydroxy formamide derivatives and their use
MX2020001875A (es) Forma polimorfica de tg02.
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
MX383754B (es) Composiciones para usarse en el tratamiento de la intolerancia al gluten y padecimientos relacionados.
MX2020000636A (es) Proteinas sinteticas y usos terapeuticos de las mismas.
PH12019502483A1 (en) Brimonidine for use and clinical trial design for geographic atrophy due to age-related macular degeneration
PH12019502380A1 (en) Compositions and methods for treating retinopathy
MX2017000118A (es) Biocontrol de enfermedades asociadas a la semilla en plantulas.
UA87159U (ru) Способ предпосевной обработки семян пшеницы
WO2019126695A3 (en) Methods and pharmaceutical compositions for treating candida auris in blood